In vivo imaging of Aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer68Ga-NOTA-c(NGR)

European Journal of Pharmaceutical Sciences

Volumn 69, Issue , 2015, Pages 61-71

  Máté, Gábor ^a   Kertész, István ^a   Enyedi, Kata Nóra ^b   Mezo, Gábor ^b   Angyal, János ^a   Vasas, Nikolett ^a   Kis, Adrienn ^a   Szabó, Éva ^a   Emri, Miklós ^a   Bíró, Tamás ^a   Galuska, László ^a   Trencsényi, György ^a,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c SCANOMED LTD   (Hungary)

Author keywords

68Ga NODAGA c(RGD) 2; 68Ga NOTA c(NGR); Aminopeptidase N (CD13) expression; Positron emission tomography; Renal tumors; Tumor angiogenesis

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID C ASPARAGINYLGLYCYLARGININE GA 68; AMINOPEPTIDASE N RECEPTOR; GALLIUM 68; MICROSOMAL AMINOPEPTIDASE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 68GA-NODAGA-RGD; 68GA-NOTA-C(NGR); COORDINATION COMPOUND; CYCLOPEPTIDE; TRACER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SPECIFICITY; EXPERIMENTAL NEOPLASM; HETEROTOPIC TRANSPLANTATION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MESOBLASTIC NEPHROMA; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RAT; WESTERN BLOTTING; ANIMAL; DIAGNOSTIC USE; FISCHER 344 RAT; KIDNEY TUMOR; METABOLISM; PATHOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANTIGENS, CD13; COORDINATION COMPLEXES; KIDNEY NEOPLASMS; MALE; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RATS, INBRED F344; TISSUE DISTRIBUTION;

EID: 84921770352     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.01.002     Document Type: Article

References (53)

1. Antczak, C., De Meester, I., Bauvois, B., 2001. Transmembrane proteases as disease markers and targets for therapy. J. Biol. Regul. Homeostasis Agents 15, 130-139.
2. Arap, W., Pasqualini, R., Ruoslahti, E., 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380.
3. Banerjee, S.R., Pomper, M.G., 2013. Clinical applications of Gallium-68. Appl. Radiat. Isot. 76, 2-13.
4. Beer, A.J., Kessler, H., Wester, H.J., Schwaiger, M., 2011. PET imaging of integrin αVβ3 expression. Theranostics 17, 48-57.
5. Borgstrom, P., Oh, P., Czarny, M., Racine, B., Schnitzer, J.E., 2013. Co-implanting orthotopic tissue creates stroma microenvironment enhancing growth and angiogenesis of multiple tumors. Version 2. F1000Res. 2,129.
6. Buehler, A., van Zandvoort, M.A., Stelt, B.J., Hackeng, T.M., Schrans-Stassen, B.H., Bennaghmouch, A., Hofstra, L., Cleutjens, J.P., Duijvestijn, A., Smeets, M.B., de Kleijn, D.P., Post, M.J., de Muinck, E.D., 2006. CNGR, a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. 26, 2681-2687.
7. Carmeliet, P., Jain, R.K., 2000. Angiogenesis in cancer and other diseases. Nature 407, 249-257.
8. Chaffer, C.L., Weinberg, R.A., 2011. A perspective on cancer cell metastasis. Science 331, 1559-1564.
9. Chen, K., Ma, W., Li, G., Wang, J., Yang, W., Yap, L.P., Hughes, L.D., Park, R., Conti, P.S., 2013. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression. Mol. Pharm. 10, 417-427.
10. Colombo, G., Curnis, F., De Mori, G.M., Gasparri, A., Longoni, C., Sacchi, A., Longhi, R., Corti, A., 2002. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem. 27749, 47891-47897.
11. Corti, A., Curnis, F., 2011. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr. Pharm. Biotechnol. 12, 1128-1134.
12. Corti, A., Curnis, F., Arap, W., Pasqualini, R., 2008. The neovasculature homing motif NGR, more than meets the eye. Blood 112, 2628-2635.
13. Corti, A., Pastorino, F., Curnis, F., Arap, W., Ponzoni, M., Pasqualini, R., 2011. Targeted drug delivery and penetration into solid tumors. Med. Res. Rev. 32, 1078-1091.
14. Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., Corti, A., 2000. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N CD13. Nat. Biotechnol. 18, 1185-1190.
15. Curnis, F., Sacchi, A., Gasparri, A., Longhi, R., Bachi, A., Doglioni, C., Bordignon, C., Traversari, C., Rizzardi, G.P., Corti, A., 2008. Isoaspartate-glycine-arginine, a new tumor vasculature targeting motif. Cancer Res. 68, 7073-7082.
16. Dezso, B., Rady, P., Morocz, I., Varga, E., Gomba, S., Poulsen, K., Kertai, P., 1991. Morphological and immunohistochemical characteristics of dimethylnitrosamine-induced malignant mesenchymal renal tumor in F344 rats. J. Cancer Res. Clin. Oncol. 116, 372-378.
17. Dijkgraaf, I., van de Vijver, P., Dirksen, A., Hackeng, T.M., 2013. Synthesis and application of cNGR-containing imaging agents for detection of angiogenesis. Bioorg. Med. Chem. 21, 3555-3564.
18. Ellis, L.M., Liu, W., Ahmad, S.A., Fan, F., Jung, Y.D., Shaheen, R.M., Reinmuth, N., 2001. Overview of angiogenesis, biologic implications for antiangiogenic therapy. Semin. Oncol. 28, 94-104.
19. Faintuch, B.L., Oliveira, E.A., Targino, R.C., Moro, A.M., 2014. Radiolabeled NGR phage display peptide sequence for tumor targeting. Appl. Rad. Isot. 86, 41-45.
20. Folkman, J., 2002. Role of angiogenesis in tumor growth and metastasis. Semi. Oncol. 29, 15-18.
21. Fontijn, D., Duyndam, M.C.A., van Berkel, M.P.A., Yuana, Y., Shapiro, L.H., Pinedo, H.M., Broxterman, H.J., Boven, E., 2006. CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells. Br. J. Cancer 94, 1627-1636.
22. Haubner, R., 2006. Fvb 3-integrin imaging, a new approach to characterise angiogenesis? Eur. J. Nucl. Med. Mol. Imaging. 33, 54-63.
23. Haubner, R., Wester, H.J., Reuning, U., Senekowitsch-Schmidtke, R., Diefenbach, B., Kessler, H., Stöcklin, G., Schwaiger, M., 1999. Radiolabeled αvβ3 integrin antagonists, a new class of tracers for tumor targeting. J. Nucl. Med. 40, 1061-1071.
24. Haubner, R., Wester, H.J., Burkhart, F., Senekowitsch-Schmidtke, R., Weber, W., Goodman, S.L., Kessler, H., Schwaiger, M., 2001. Glycosylated RGD-containing peptides, tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336.
25. Higuchi, T., Bengel, F.M., Seidl, S., Watzlowik, P., Kessler, H., Hegenloh, R., Reder, S., Nekolla, S.G., Wester, H.J., Schwaiger, M., 2008. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc. Res. 78, 395-403.
26. Kerbel, R.S., 2003. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2, S134-139.
27. Lajtos, I., Emri, M., Kis, S.A., Opposits, G., Potari, N., Kiraly, B., Nagy, F., Tron, L., Balkay, L., 2013. Performance evaluation and optimization of the MiniPET-II scanner. Nucl. Instrum. Method 707, 26-34.
28. Ma, W., Kang, F., Wang, Z., Yang, W., Li, G., Ma, X., Li, G., Chen, K., Zhang, Y., Wang, J., 2013. 99mTc-labeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice. Amino Acids 44, 1337-1345.
29. Ma, W., Wang, Z., Yang, W., Ma, X., Kang, F., Wang, J., 2014. Biodistribution and SPECT imaging study of 99m.Tc labeling NGR peptide in nude mice bearing human HepG2 hepatoma. BioMed Res. Int. 2014. http://dx.doi.org/10.1155/2014/618096.
30. Negussie, A.H., Miller, J.L., Reddy, G., Drake, S.K., Wood, B.J., Dreher, M.R., 2010. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J. Control. Release 143, 265-273.
31. Notni, J., Šimeček, J., Hermann, P., Wester, H.J., 2011. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem. Eur. J. 17, 14718-14722.
32. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., et al., 2000. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722-727.
33. 68Ga-NODAGA-RGD is a suitable substitute for 18.F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl. Med. Biol. 39, 777-784.
34. Rozsa, D., Trencsenyi, G., Kertai, P., Marian, T., Nagy, G., Banfalvi, G., 2009. Lymphatic spread of mesenchymal renal tumor to metastatic parathymic lymph nodes in rat. Histol. Histopathol. 24, 1367-1379.
35. Rundhaug, J.E., 2005. Matrix metalloproteinases and angiogenesis. J. Cell Mol. Med. 9, 267-285.
36. Seong Choe, Y., Lee, K.H., 2007. Targeted in vivo imaging of angiogenesis, present status and perspectives. Curr. Pharm. Des. 13, 17-31.
37. 68Ga-labeled cyclic NGR peptide for MicroPET imaging of CD13 receptor expression. Molecules 19, 11600-11612.
38. 68Ga-labeled NGR and RGD peptides in HT-1080 tumor xenografts using microPET imaging. Amino Acids 2014. http://dx.doi.org/10.1007/s00726-014-1788-x.
39. Simons, M., 2005. Angiogenesis, where do we stand now? Circulation 111, 1556-1566.
40. 68Ga-agents. Appl. Radiat. Isot. 76, 14-23.
41. Su, L., Cao, J., Jia, Y., Zhang, X., Fang, H., Xu, W., 2012. Development of synthetic Aminopeptidase N/CD13 inhibitors to overcome cancer metastasis and angiogenesis. ACS Med. Chem. Lett. 3, 959-964.
42. Trencsenyi, G., Kertai, P., Bako, F., Hunyadi, J., Marian, T., Hargitai, Z., Pocsi, I., Muranyi, E., Hornyak, L., Banfalvi, G., 2009. Renal capsule-parathymic lymph node complex, a new in vivo metastatic model in rats. Anticancer Res. 29, 2121-2126.
43. Trencsenyi, G., Nagy, G., Kahlik, B., Nemeth, E., Kertai, P., Kiss, A., Banfalvi, G., 2014. Lymphoid metastasis of rat My2/De leukemia. Leuk. Res. 5, 586-593.
44. van Hensbergen, Y., Broxterman, H.J., Rana, S., van Diest, P.J., Duyndam, M.C., Hoekman, K., Pinedo, H.M., Boven, E., 2004. Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin. Cancer Res. 10, 1180-1191.
45. 68Ga-radiopharmaceutical development. Theranostics 4, 47-80.
46. Wang, R.E., Niu, Y., Wu, H., Amin, M.N., Cai, J., 2011. Development of NGR peptide-based agents for tumor imaging. Am. J. Nucl. Med. Mol. Imaging. 1, 36-46.
47. 68Ga-labeling technique for proteins. J. Nucl. Med. 52, 586-591.
48. Wester, H.J., 2007. Nuclear imaging probes, from bench to bedside. Clin. Cancer Res. 13, 3470-3481.
49. Workman, P., Twentyman, P., Balkwill, F., et al., 1988. United Kingdom coordinating committee on cancer research UKCCCR. Guidelines for the welfare of animals in experimental neoplasia. Br. J. Cancer 77, 1-10.
50. Wu, C., Li, F., Niu, G., Chen, X., 2013. PET imaging of inflammation biomarkers. Theranostics 3, 448-466.
51. Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., Holash, J., 2000. Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248.
52. Yang, Y., Yang, Y., Xie, X., Cai, X., Zhang, H., Gong, W., Wang, Z., Mei, X., 2014. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating petide-doxorubicin conjugate for tumor-specific therapy. Biomaterials 35, 4368-4381.
53. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET. Nucl. Med. Biol. 41, 268-275.